WillItSurvive
Pharma and healthcare groups · United States

Zoetis

zoetis.com ↗

Zoetis makes drugs and vaccines for pets and livestock, sold through vets worldwide.

Defensible for now
Assessed 20 July 2026 · Evidence as of 20 July 2026
Real protection, with named pressure against it.
On the recordSince 20 July 2026 · Checkable from August 6, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report
The call

Zoetis still leads animal health by scale and vet access, but Elanco is chewing into its biggest franchises while a securities lawsuit and guidance cuts pile on.

Zoetis makes medicines and vaccines for pets and farm animals and sells them directly to vets in over 100 countries. It is hard to copy or replace because the government has approved its drugs, it knows how to make complex biologics, and vets already trust and use its products. However, a competitor called Elanco is taking away sales in three of Zoetis's biggest products right now, which is shrinking the company's growth. The one thing that could change everything is whether Elanco keeps winning only in those three products or starts taking sales in Zoetis's other medicines too, which would mean the damage is much bigger than it looks today.

Why
01
AI pressure: None apparent. AI helps discover animal drugs faster but no AI product treats animals or replaces vets, so this is not an AI story. Could AI do the core job? Unlikely.
02
Bigger players: Elanco Animal Health. Elanco's Zenrelia and Credelio Quattro are pulling share from Zoetis in dermatology and parasiticides right now, not someday. Could a giant copy it? No, they are blocked.
03
What protects it. FDA approval barriers, biologics manufacturing scale, and direct vet-clinic distribution across 100+ countries keep new entrants out, but not Elanco.
What would change this call
Zoetis Q2 2026 earnings on August 6, 2026 showing companion-animal share trend. Stabilizing share means Elanco erosion contained; further decline means losses spreading.
Outcome of securities class action lead plaintiff deadline July 27, 2026. Would show whether Zoetis concealed known competitive weakness from investors.
Whether Zoetis fills its vacant R&D president role (open since 2025). Prolonged vacancy signals leadership gaps in responding to Elanco's product launches.
Key numbers
  • FY2025 revenue $9.47 billion (2025-12-31)
  • Stock fell ~21.5% on May 7, 2026 (2026-05-07)
  • Companion animal share 21-28% of category (2025-12-31)
Named risks
  • Active securities class action alleging concealment of Librela and share-loss issues, deadline July 27, 2026. Severity: high
  • Companion animal franchise erosion in Librela, Simparica Trio, Apoquel/Cytopoint to Elanco. Severity: high
  • Two consecutive FY2026 guidance cuts reflecting weakening demand signals. Severity: medium
  • R&D president role unfilled since 2025 retirement, leadership continuity gap. Severity: medium
  • Stock down roughly 65% from all-time high of $249.27, heightened investor scrutiny. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Elancolosing toZenrelia took share from Apoquel/Cytopoint in dermatology, disclosed May 6, 2026
Elancolosing toCredelio Quattro eroded Simparica Trio share in parasiticides, disclosed May 6, 2026
IDEXXcontestingZoetis expanding Vetscan Imagyst/OptiCell AI diagnostics to compete for clinic diagnostics share, 2025-2026
Merck Animal HealthcontestingTop five players including Merck hold ~40% combined global animal health share as of Feb 2026
Boehringer IngelheimcontestingRanks among top five global animal health firms alongside Zoetis, per Feb 2026 market report
Questions people ask
Is Zoetis profitable in 2026?
Yes. Zoetis posted FY2025 revenue of $9.47 billion, up 2.28% year over year, and Q1 2026 revenue of roughly $2.26 to $2.3 billion. However Q1 2026 EPS of $1.53 missed the $1.60 consensus, and management cut FY2026 guidance on May 6, 2026 to $9.68 to $9.96 billion, down from February's $9.825 to $10.025 billion forecast.
Is Zoetis losing market share to Elanco?
Yes, in specific franchises. Zoetis disclosed on May 6, 2026 that Elanco's Zenrelia is taking share from Apoquel and Cytopoint in dermatology, while Credelio Quattro is eroding Simparica Trio in parasiticides. The stock fell about 21.5%, from $111.22 to $87.31, on that disclosure on May 7, 2026.
Who owns Zoetis?
Zoetis is fully independent and publicly traded on NYSE as ZTS, spun off from Pfizer starting with a February 2013 IPO. Pfizer has since fully divested its stake. Top institutional holders include BlackRock, with about 35.6 million shares, and Vanguard entities holding roughly 72 million shares combined as of mid-2026.
Could AI replace Zoetis's diagnostics business?
No, AI is a tool Zoetis uses to strengthen diagnostics, not a threat replacing it. It launched AI Masses cytology on Vetscan Imagyst in June 2025, won a 2025 award for Vetscan OptiCell, and announced acquiring teleradiology platform VitalRADS on July 13, 2026, expected to close Q3 2026, adding AI-assisted reporting.
What is Zoetis's biggest competitor?
Elanco Animal Health is Zoetis's most direct rival, gaining ground in dermatology with Zenrelia against Apoquel and Cytopoint, and in parasiticides with Credelio Quattro against Simparica Trio, disclosed May 6, 2026. Other peers include Merck Animal Health, Boehringer Ingelheim, and IDEXX, with the top five holding about 40% of the global market.
Is Zoetis facing a lawsuit in 2026?
Yes. A securities class action, S.D.N.Y. Case No. 1:26cv04401, alleges Zoetis concealed weakening Librela safety and adoption plus competitive erosion in Simparica Trio, Apoquel, and Cytopoint between January 14, 2025 and May 6, 2026. The lead plaintiff deadline is July 27, 2026.
Timeline
  • 2026-08-06Q2 2026 earnings scheduled; consensus expects ~$2.49B revenue, $1.85 EPS
  • 2026-07-27Lead plaintiff deadline in Zoetis securities class action, S.D.N.Y. 1:26cv04401
  • 2026-07-13Zoetis announces agreement to acquire VitalRADS teleradiology platform
  • 2026-05-07Stock falls ~21.5%, from $111.22 to $87.31, on share-loss disclosure
  • 2026-05-06Q1 2026 results reported; FY2026 guidance cut to $9.68-$9.96B
  • 2026-02-11FY2025 results reported: revenue $9.47B, up 2.28% YoY
  • 2025-09-30FDA conditionally approves Dectomax-CA1 for New World screwworm
  • 2025-06-02AI Masses cytology feature launched on Vetscan Imagyst
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Boston ScientificBecton DickinsonEli Lilly
More in Pharma and healthcare groups →
Sources